OTCPK:MDBI.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Medibio Limited, a health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Medibio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDBI.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

MDBI.F

2.4%

US Healthcare Services

-0.8%

US Market


1 Year Return

14.3%

MDBI.F

64.5%

US Healthcare Services

13.8%

US Market

Return vs Industry: MDBI.F underperformed the US Healthcare Services industry which returned 64.5% over the past year.

Return vs Market: MDBI.F matched the US Market which returned 13.8% over the past year.


Shareholder returns

MDBI.FIndustryMarket
7 Day0%2.4%-0.8%
30 Day0%-0.7%-5.0%
90 Dayn/a16.1%10.1%
1 Year14.3%14.3%65.0%64.5%16.4%13.8%
3 Year-97.7%-97.7%101.5%100.0%36.9%27.8%
5 Yearn/a164.7%161.9%85.0%64.2%

Price Volatility Vs. Market

How volatile is Medibio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medibio undervalued compared to its fair value and its price relative to the market?

1.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MDBI.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MDBI.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDBI.F is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: MDBI.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDBI.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDBI.F is good value based on its PB Ratio (1x) compared to the US Healthcare Services industry average (5.2x).


Next Steps

Future Growth

How is Medibio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

38.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medibio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Medibio performed over the past 5 years?

-0.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MDBI.F is currently unprofitable.

Growing Profit Margin: MDBI.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDBI.F is unprofitable, and losses have increased over the past 5 years at a rate of 0.2% per year.

Accelerating Growth: Unable to compare MDBI.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDBI.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.8%).


Return on Equity

High ROE: MDBI.F has a negative Return on Equity (-30.71%), as it is currently unprofitable.


Next Steps

Financial Health

How is Medibio's financial position?


Financial Position Analysis

Short Term Liabilities: MDBI.F's short term assets (A$861.7K) do not cover its short term liabilities (A$1.4M).

Long Term Liabilities: MDBI.F has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: MDBI.F is debt free.

Reducing Debt: MDBI.F has no debt compared to 5 years ago when its debt to equity ratio was 40.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDBI.F has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: MDBI.F is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Medibio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDBI.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDBI.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDBI.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDBI.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDBI.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Claude Solitario

0.67

Tenure

AU$18,630

Compensation

Mr. Claude Solitario is the Managing Director of Medibio Limited since January 9, 2020 and also serves its Chief Executive Officer. He has been Director at Medibio Ltd. since December 31, 2018. He served a ...


Leadership Team

NamePositionTenureCompensationOwnership
Claude Solitario
Managing Director0.67yrAU$18.63k3.87%
A$ 439.6k
Melanie Jaye Leydin
Joint Company Secretary & Director1.58yrsAU$147.63kno data
Renee Stanton-Horne
Operations & Account Manager0.67yrno datano data
Stephanie Ottens
Investor Relations Directorno datano datano data
Josh Purdy
Public Relations Directorno datano datano data
Michael Player
Head of Research4.5yrsno datano data
Matthew Flax
Head of Algorithm Development Team4.5yrsno datano data
Archie Defillo
Chief Medical Officer & Member of the Scientific Advisory Board2.42yrsno datano data
Jennifer Solitario
Senior Vice President of Corporate Health2yrsno datano data
Massimiliano Grassi
Head of Artificial Intelligence0.67yrno datano data
Mathew Watkins
Joint Company Secretary1.83yrsno datano data

1.9yrs

Average Tenure

Experienced Management: MDBI.F's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Claude Solitario
Managing Director0.67yrAU$18.63k3.87%
A$ 439.6k
Melanie Jaye Leydin
Joint Company Secretary & Director1.58yrsAU$147.63kno data
Archie Defillo
Chief Medical Officer & Member of the Scientific Advisory Board2.42yrsno datano data
Wallace Mendelson
Member of Scientific Advisory Board2.42yrsno datano data
Peter Carlisle
Chairman of Growth & Advocacy Advisory Board and Non-Executive & Lead Independent Director1.08yrsAU$72.79k0.0093%
A$ 1.1k
Patrick Kennedy
Member of Growth & Advocacy Advisory Board1.08yrsAU$64.09kno data
Michael Phelps
Member of Growth & Advocacy Advisory Board1.08yrsAU$61.61kno data
Martin Chapman
Member of Scientific Advisory Board2.42yrsno datano data
Joel Ehrenkranz
Member of Scientific Advisory Board2.42yrsno datano data
Mark Frye
Member of Scientific Advisory Board2.42yrsno datano data
Lawrence Hunter
Member of Scientific Advisory Board2.42yrsno datano data
Giampaolo Perna
Member of Scientific Advisory Board2.42yrsno datano data

2.4yrs

Average Tenure

Experienced Board: MDBI.F's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.4%.


Top Shareholders

Company Information

Medibio Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medibio Limited
  • Ticker: MDBI.F
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$16.172m
  • Listing Market Cap: AU$11.345m
  • Shares outstanding: 1.35b
  • Website: https://www.medibio.com.au

Location

  • Medibio Limited
  • 8696 Eagle Creek Circle
  • Savage
  • Minnesota
  • 55378
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEBASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2001
MEBCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2001
MDBI.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 2001
BPNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2001

Biography

Medibio Limited, a health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. It is involved in the research, development, a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/27 06:35
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.